{"Clinical Trial ID": "NCT00191152", "Intervention": ["INTERVENTION 1:", "- Gemcitabine Plus Docetaxel", "- gemcitabine 1000 milligrams per square metre (mg/m2) intravenously, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenously, day 1 every 21 days.", "The treatment continues until the progression of the disease at which the cross-treatment begins.", "INTERVENTION 2:", "Docetaxel Plus Capecitabine", "Docetaxel 75 mg/m2, intravenously, day 1 every 21 days plus capecitabine 1000 mg/m2, orally, twice daily, day 1-14 every 21 days. Treatment continues until disease progression, at which the cross-treatment begins."], "Eligibility": ["Incorporation criteria:", "- Histological or cytological confirmation of breast cancer with locally advanced and/or metastatic disease", "Patients may have received neo-adjuvant or taxane adjuvant therapy prior to 6 months or more since the end of treatment.", "Patients may have had 0-1, but not more than one chemotherapy treatment for metastatic disease", "Patients must have a measurable or non-measurable disease (evaluable)", "Previous radiation therapy allowed radiation therapy of less than 25% of the bone marrow", "- Exclusion criteria:", "Second primary malignancy (except in situ cervix carcinoma or non-melanomatous carcinoma sufficiently treated with skin or other malignancy treated at least 5 years previously without evidence of recurrence)", "\u2022 Parenchymic or leptomenic cerebral metastases", "\u2022 Peripheral neuropathy greater than or equal to the second year", "Prior treatment with gemcitabine and capecitabine will not be permitted. Prior treatment with a taxane in the metastatic setting will not be permitted. Prior treatment with taxane in the neoadjuvant or adjuvant setting is permitted if the end of treatment is greater than or equal to 6 months prior to registration.", "\u2022 Active heart disease not controlled by treatment and/or myocardial infarction in the previous 6 months.", "- Concomitant Herceptin is not allowed"], "Results": ["Performance measures:", "Time of disease progression (initial treatment)", "The time required to advance the disease at the beginning of treatment was defined as the number of months between the date of randomization and the date of the first documented progression of the disease or the date of death due to the disease under study, whichever occurs first. The DTCD censored at the earliest: (1) the date of death not due to the disease; or (2) the date of last contact for live participants without progression of the disease; or (3) the date of commencement of another anti-tumour treatment; or (4) the date of the first cross dose of the treatment.", "Time limit: Randomization date at the earliest date of first documented date of progression of disease or date of death if participant died due to illness under study (up to 82 months)", "Results 1:", "Title of the arm/group: Gemcitabine Plus Docetaxel", "Description of the arm/group: gemcitabine 1000 milligrams per square metre (mg/m2) intravenously, days 1 and 8 every 21 days plus docetaxel 75 mg/m2, intravenously, day 1 every 21 days.", "The treatment continues until the progression of the disease at which the cross-treatment begins.", "Total number of participants analysed: 239", "Median (95% confidence interval)", "Unit of measure: months 9.28 (7.73 to 10.79)", "Results 2:", "Title of the arm/group : Docetaxel Plus Capecitabine", "Description arm/group: docetaxel 75 mg/m2, intravenous, day 1 every 21 days plus capecitabine 1000 mg/m2, oral, twice daily, days 1-14 every 21 days. Treatment continues until disease progression, at which the cross-treatment begins.", "Total number of participants analysed: 236", "Median (95% confidence interval)", "Unit of measure: month 8.88 (7.37 to 11.05)"], "Adverse Events": ["Undesirable Events 1:", "Total: 72/237 (30.38 per cent)", "Anemia 2/237 (0.84%)", "Intravascular coagulation disseminate 1/237 (0.42%)", "9/237 (3.80%)", "- Leucocytosis 1/237 (0.42%)", "Leukopenia 6/237 (2.53%)", "- Lymphopenia 1/237 (0.42%)", "- Neutropenia 25/237 (10.55%)", "Thrombocytopenia 2/237 (0.84%)", "Atrial fibrillation 0/237 (0.00 %)", "Congestive heart failure 2/237 (0.84%)", "Adverse Events 2:", "Total: 55/226 (24.34 per cent)", "Anemia 1/226 (0.44%)", "Disseminate intravascular coagulation 0/226 (0.00 %)", "9/226 (3.98%)", "- Leucocytosis 0/226 (0.00 %)", "Leukopenia 2/226 (0.88%)", "- Lymphopenia 0/226 (0.00 %)", "- Neutropenia 7/226 (3.10%)", "Thrombocytopenia 0/226 (0.00 %)", "Atrial fibrillation 1/226 (0.44%)", "Congestive heart failure 0/226 (0.00 %)"]}